Jonathan D Schwartz

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi Nephrectomy for metastatic renal-cell cancer
    Jonathan D Schwartz
    N Engl J Med 346:1095-6. 2002
  2. ncbi Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials
    Jonathan D Schwartz
    Mount Sinai School of Medicine, Medical Oncology, New York, NY 10029, USA
    Lancet Oncol 3:593-603. 2002
  3. ncbi Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma
    Jonathan D Schwartz
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Anticancer Drugs 15:439-52. 2004
  4. ncbi Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression
    Jonathan D Schwartz
    Hematology Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 10:718-27. 2005
  5. ncbi Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma
    Diane L Reidy
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Anticancer Drugs 15:427-37. 2004
  6. ncbi Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
    Abby B Siegel
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032 3784, USA
    J Clin Oncol 26:2992-8. 2008
  7. ncbi Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis
    Sasan Roayaie
    Recanati Miller Transplantation Institute, Department of Medicine, Mount Sinai Medical Center, Mount Sinai NYU Health System, New York, NY 10029, USA
    Liver Transpl 10:534-40. 2004
  8. ncbi Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells
    Zhaojing Zhong
    Department of Antibody Technology and Immunology, Clinical Research, and Research, ImClone Systems, New York, New York 10014, USA
    Clin Cancer Res 16:1191-205. 2010
  9. ncbi Case 13-2006: a man with a bone mass and lesions in the liver
    Jonathan D Schwartz
    N Engl J Med 355:422-3; author reply 423. 2006
  10. ncbi Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:706-12. 2004

Research Grants

  1. Cytokine Inhibition in Hepatocellular Carcinoma
    Jonathan Schwartz; Fiscal Year: 2005

Collaborators

Detail Information

Publications10

  1. ncbi Nephrectomy for metastatic renal-cell cancer
    Jonathan D Schwartz
    N Engl J Med 346:1095-6. 2002
  2. ncbi Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials
    Jonathan D Schwartz
    Mount Sinai School of Medicine, Medical Oncology, New York, NY 10029, USA
    Lancet Oncol 3:593-603. 2002
    ..Other adjuvant modalities (mostly tested in small, preliminary settings) may confer benefit after potentially curative resection of HCC...
  3. ncbi Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma
    Jonathan D Schwartz
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Anticancer Drugs 15:439-52. 2004
    ..More adequately powered, rigorously conducted studies will hopefully identify useful chemo-, radio-, immuno-, embolization-based and biologically targeted therapies during the next decade...
  4. ncbi Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression
    Jonathan D Schwartz
    Hematology Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 10:718-27. 2005
    ..Systemic therapy is minimally effective in HCC and tumor angiogenesis is a potential therapeutic target...
  5. ncbi Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma
    Diane L Reidy
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Anticancer Drugs 15:427-37. 2004
    ..There is limited evidence and consensus regarding optimal choice and dosage of chemical agents utilized for hepatic artery chemoembolization...
  6. ncbi Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
    Abby B Siegel
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032 3784, USA
    J Clin Oncol 26:2992-8. 2008
    ..To determine the clinical and biologic effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC)...
  7. ncbi Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis
    Sasan Roayaie
    Recanati Miller Transplantation Institute, Department of Medicine, Mount Sinai Medical Center, Mount Sinai NYU Health System, New York, NY 10029, USA
    Liver Transpl 10:534-40. 2004
    ..Nonetheless, some patients with recurrence can be expected to live for a considerable period of time. Recurrent disease should be treated surgically when possible, because surgery is independently associated with longer survival...
  8. ncbi Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells
    Zhaojing Zhong
    Department of Antibody Technology and Immunology, Clinical Research, and Research, ImClone Systems, New York, New York 10014, USA
    Clin Cancer Res 16:1191-205. 2010
    ..We investigated the therapeutic efficacy of anti-TGFbeta receptor II (TGFbeta RII) antibody in controlling metastasis and tumor growth as well as enhancing antitumor immunity in preclinical tumor models...
  9. ncbi Case 13-2006: a man with a bone mass and lesions in the liver
    Jonathan D Schwartz
    N Engl J Med 355:422-3; author reply 423. 2006
  10. ncbi Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:706-12. 2004
    ..To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu...

Research Grants1

  1. Cytokine Inhibition in Hepatocellular Carcinoma
    Jonathan Schwartz; Fiscal Year: 2005
    ....